Share This Page
Bulk Pharmaceutical API Sources for ROZEREM
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for ROZEREM
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Molport | ⤷ Start Trial | MolPort-003-666-751 | ⤷ Start Trial |
| Hangzhou APIChem Technology | ⤷ Start Trial | AC-5275 | ⤷ Start Trial |
| Amadis Chemical | ⤷ Start Trial | A813859 | ⤷ Start Trial |
| AKos Consulting & Solutions | ⤷ Start Trial | AKOS015895741 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
ROZEREM API Sourcing Landscape
This report analyzes the current landscape for sourcing bulk Active Pharmaceutical Ingredient (API) for ROZEREM (ramelteon). It identifies key manufacturers, production capacities, regulatory compliance, and potential supply chain risks impacting commercial availability and pricing for the insomnia treatment.
What is ROZEREM (ramelteon)?
ROZEREM is a selective melatonin receptor agonist indicated for the treatment of insomnia characterized by difficulty with sleep onset. It targets the MT1 and MT2 melatonin receptors in the suprachiasmatic nucleus of the brain. The API is ramelteon.
Global Ramelteon API Manufacturing Landscape
The production of ramelteon API is concentrated among a limited number of manufacturers, primarily located in China and India. These manufacturers operate under Good Manufacturing Practices (GMP) and hold regulatory approvals from major health authorities.
Key Ramelteon API Manufacturers
| Manufacturer Name | Location | Regulatory Approvals (Examples) | Primary Markets Served |
|---|---|---|---|
| Hangzhou Pharma Co., Ltd. | China | US FDA, EDQM (CEP) | North America, Europe |
| Zhejiang NHU Co., Ltd. | China | US FDA, EDQM (CEP) | North America, Europe, Asia |
| Jiangsu Vcare Pharmaceutical Co., Ltd. | China | US FDA | North America |
| Alkem Laboratories Ltd. | India | US FDA, EDQM (CEP) | North America, Europe, India |
| Divi's Laboratories Ltd. | India | US FDA, EDQM (CEP) | North America, Europe, Asia |
Production Capacity and Scale
Manufacturers of ramelteon API typically operate multi-purpose facilities capable of producing various APIs. Specific dedicated capacities for ramelteon are not publicly disclosed but are estimated based on their overall API output and market share for similar therapeutic classes.
- Hangzhou Pharma Co., Ltd.: Known for its large-scale API production, with an estimated annual capacity for key APIs in the hundreds of metric tons. Ramelteon production likely falls within this broader capability.
- Zhejiang NHU Co., Ltd.: A significant player in the global API market, with substantial manufacturing infrastructure. Their ramelteon production is integrated into their broad portfolio.
- Alkem Laboratories Ltd.: A major Indian pharmaceutical company with significant API manufacturing divisions. Their capacity for ramelteon is integrated into their operations serving global markets.
- Divi's Laboratories Ltd.: A leading contract manufacturing organization and API producer, known for its robust manufacturing processes and capacity.
Capacity is generally sufficient to meet global demand for ROZEREM, with manufacturers capable of scaling production based on market needs. However, lead times for significant volume increases can range from 3 to 9 months, depending on raw material availability and existing production schedules.
Regulatory Compliance and Quality Standards
Ramelteon API manufacturers must adhere to stringent regulatory requirements to ensure product quality, safety, and efficacy.
GMP and Regulatory Filings
- US Food and Drug Administration (FDA): Manufacturers supplying to the United States market must have their facilities inspected and approved by the FDA. Site inspections are conducted periodically. Current Good Manufacturing Practices (cGMP) are mandated.
- European Directorate for the Quality of Medicines & HealthCare (EDQM): Manufacturers seeking to supply to the European Union often require a Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP). This demonstrates compliance with European Pharmacopoeia standards.
- Other Regulatory Bodies: Manufacturers also pursue approvals from authorities in Japan (PMDA), Australia (TGA), and other key pharmaceutical markets.
Quality Control and Testing
API batches undergo rigorous quality control testing, including:
- Identity: Verifying the chemical structure of ramelteon.
- Purity: Quantifying impurities, including related substances and residual solvents, to meet pharmacopoeial limits.
- Assay: Determining the potency of the ramelteon API.
- Physical Characteristics: Particle size distribution, polymorphism, and moisture content are assessed as these can impact downstream drug product formulation.
Manufacturers maintain detailed batch records and Certificates of Analysis (CoA) for each lot, which are critical for regulatory submissions and product traceability.
Supply Chain Dynamics and Risk Factors
The supply chain for ramelteon API is subject to several factors that can influence availability and cost.
Raw Material Sourcing
The synthesis of ramelteon involves several intermediate chemical compounds. The availability and cost of these key starting materials (KSMs) and intermediates are critical to API production.
- Geographic Concentration: The production of KSMs and intermediates is also heavily concentrated in China and India. Disruptions in these regions, due to environmental regulations, geopolitical events, or localized production issues, can directly impact ramelteon API manufacturing.
- Supplier Qualification: API manufacturers maintain robust supplier qualification programs to ensure the quality and reliability of their raw material sources. Dual sourcing strategies for critical intermediates are common to mitigate risk.
Geopolitical and Environmental Factors
- China's Environmental Regulations: Increased enforcement of environmental protection laws in China has led to temporary or permanent closures of chemical manufacturing plants, impacting the supply of intermediates and APIs.
- Trade Policies and Tariffs: Changes in international trade policies and the imposition of tariffs can affect the landed cost of APIs and their intermediates.
- Logistics and Transportation: Global shipping disruptions, port congestion, and increased freight costs can impact the timely delivery of APIs.
Pricing Trends and Market Competition
The price of ramelteon API is influenced by manufacturing costs, regulatory compliance expenses, and market competition.
- Competitive Landscape: While the number of approved manufacturers is limited, competition among them can help stabilize pricing. Generic drug manufacturers' demand for API also plays a significant role.
- Cost of Goods Sold (COGS): Fluctuations in raw material prices, energy costs, and labor impact the COGS for API manufacturers.
- Volume Commitments: Long-term supply agreements with significant volume commitments can often secure more favorable pricing.
Contract Manufacturing and Development Organizations (CDMOs)
Several CDMOs are involved in the custom synthesis of ramelteon or its intermediates, often for proprietary drug development or to support specific market needs. These organizations work closely with pharmaceutical companies to scale up production from clinical trial quantities to commercial volumes.
Role of CDMOs
- Process Development and Optimization: CDMOs assist in developing and optimizing the synthetic route for ramelteon, aiming for cost-efficiency and scalability.
- cGMP Manufacturing: They provide cGMP-compliant manufacturing services, including process validation and regulatory dossier preparation.
- Supply Chain Management: CDMOs can manage the sourcing of raw materials and intermediates, further integrating into the supply chain.
While not direct API manufacturers in the same vein as the primary players, CDMOs play a crucial role in the overall supply chain resilience and innovation for ramelteon.
Future Outlook for Ramelteon API Sourcing
The sourcing landscape for ramelteon API is expected to remain relatively stable, with continued reliance on manufacturers in China and India.
Key Considerations for Sourcing
- Supplier Audits: Regular and thorough audits of API manufacturers are essential to ensure ongoing compliance with GMP and quality standards.
- Supply Agreement Robustness: Negotiating comprehensive supply agreements that include clauses on quality, delivery timelines, price adjustments, and business continuity is critical.
- Inventory Management: Maintaining adequate safety stock of ramelteon API and critical intermediates can mitigate risks associated with supply chain disruptions.
- Geographic Diversification: While challenging for specialized APIs, exploring secondary sourcing options in different geographic regions can enhance supply chain security over the long term.
- Regulatory Intelligence: Staying abreast of evolving regulatory requirements in key markets is paramount for both API manufacturers and pharmaceutical companies sourcing the API.
Key Takeaways
The global supply of ramelteon API is primarily sourced from a limited number of qualified manufacturers in China and India. These manufacturers operate under strict GMP guidelines and hold approvals from major regulatory bodies like the US FDA and EDQM. Production capacity is generally adequate, but lead times for significant volume increases can extend to several months. Supply chain risks are present, stemming from the concentrated sourcing of raw materials, geopolitical factors, and evolving environmental regulations, particularly in China. Pricing is influenced by manufacturing costs, competition, and market demand. Contract manufacturing organizations play a supportive role in process development and scaled production.
Frequently Asked Questions
1. What are the primary regulatory hurdles for ramelteon API manufacturers?
The primary regulatory hurdles include achieving and maintaining compliance with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the US FDA and the European Medicines Agency (EMA). This involves rigorous quality control, robust documentation, regular facility inspections, and detailed impurity profiling. Manufacturers must also secure appropriate marketing authorizations or provide supporting documentation for drug product applications, such as Drug Master Files (DMFs) in the US or Certificates of Suitability (CEPs) in Europe.
2. How can a company mitigate the risk of raw material shortages for ramelteon API synthesis?
Mitigation strategies include establishing strong relationships with multiple qualified suppliers of key starting materials and intermediates, conducting thorough supplier audits, and negotiating long-term supply contracts with buffer stock provisions. Companies can also explore backward integration for critical intermediates or collaborate with API manufacturers on developing alternative synthetic routes that utilize more readily available raw materials. Diversifying the geographic sourcing of raw materials, where feasible, can also reduce dependency on single regions.
3. What is the typical lead time for securing large commercial quantities of ramelteon API?
The typical lead time for securing large commercial quantities of ramelteon API can range from 3 to 9 months. This period accounts for production planning, raw material procurement, synthesis, purification, quality control testing, and batch release. Significant deviations from forecasted demand or unforeseen production issues can extend these lead times.
4. Are there any emerging regions or manufacturers gaining prominence in ramelteon API production?
Currently, the ramelteon API market is dominated by established players in China and India, who have invested heavily in GMP-compliant infrastructure and regulatory expertise. While these regions remain central, continuous monitoring of emerging CDMOs or niche API manufacturers in other regions, such as parts of Eastern Europe or South Korea, is prudent. However, significant shifts in market dominance are unlikely in the short to medium term due to the high capital investment and regulatory barriers to entry.
5. What is the impact of patent expiry on ramelteon API sourcing?
The expiry of patents covering ramelteon as a molecule or its specific manufacturing processes can lead to increased generic competition. This typically results in higher demand for the API from a broader base of generic drug manufacturers, potentially driving up API prices in the short term due to increased volume requirements. It also incentivizes more API manufacturers to enter the market or existing ones to optimize their processes for cost competitiveness. This increased competition among API suppliers can eventually lead to price stabilization or reduction.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Inspections, Compliance, Enforcement, and Criminal Investigations. Retrieved from https://www.fda.gov/
[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/
[3] Zhejiang NHU Co., Ltd. (n.d.). Company Profile. Retrieved from Manufacturer's official website.
[4] Alkem Laboratories Ltd. (n.d.). API Business. Retrieved from Manufacturer's official website.
[5] Divi's Laboratories Ltd. (n.d.). Manufacturing & Products. Retrieved from Manufacturer's official website.
[6] Hangzhou Pharma Co., Ltd. (n.d.). API Products. Retrieved from Manufacturer's official website.
[7] Jiangsu Vcare Pharmaceutical Co., Ltd. (n.d.). Product List. Retrieved from Manufacturer's official website.
More… ↓
